RADIOIMMUNOGUIDED SURGERY IN GASTRIC-CANCER USING 131-I LABELED MONOCLONAL-ANTIBODY 3H11

A clinical trial of radioimmunoguided surgery (RIGS) using 131-I label ed monoclonal antibody (MAb) 3H11 was performed on 25 cases with gastr ic cancer in this study. The results showed that the route of the admi nistration of radiolabeled MAb is the key point of successful RIGS for gastric cancer. The RIGS in 19 cases in the group of submucosal injec tion via endoscope was very satisfying. For the detection of metastati c lymph nodes, the sensitivity rate of RIGS was 99.2% (118/119), the s pecificity, 97.7% (43/44), and the accuracy 98.8% (161/163). The accur acy rate in detecting tumor infiltration of the gastric wall was 95.9% (94/98), the sensitivity 94.6% (35/37), and the specificity 96.7% (59 /61). Thus, the use of RIGS may improve the radical resectability rate and possibly the overall survival rate in patients with gastric cance r. (C) 1994 Wiley-Liss, Inc.